Development and validation of a simple NAFLD clinical scoring system for identifying patients without advanced disease

By S. Harrison, D. Oliver, Hays L. Arnold, S. Gogia, B. Neuschwander‐Tetri. Gut, 2008

843 citations recorded by the source corpus.

Subfields: Endocrinology, Diabetes and Metabolism, Epidemiology, Nephrology

View Paper: https://www.semanticscholar.org/paper/7193882c8a7e3efb5c2d07b80b1e30c84b7f756b

How researchers see this paper

The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.

In Endocrinology, Diabetes and Metabolism

1. C. Day
2. S. Bellentani
3. Asociacion Latinoamericana para el Estudio del Higado

In Epidemiology

1. C. Day
2. S. Bellentani
3. V. Ratziu
4. H. Cortez‐Pinto
5. Asociacion Latinoamericana para el Estudio del Higado
6. Vincent Wai-Sun Wong
7. Y. Sumida
8. Giulio Marchesini

Citations in the corpus

• Disease progression of non-alcoholic fatty liver disease: a prospective study with paired liver biopsies at 3 years (2010, methodology): “The BARD score was the weighted sum of three variables (BMI ≥28=1 point, AST/ALT ratio ≥0.8=2 points, diabetes=1 point).”
• Comparison of laboratory tests, ultrasound, or magnetic resonance elastography to detect fibrosis in patients with nonalcoholic fatty liver disease: A meta‐analysis (2017, background): “Therefore, researchers have proposed specific models for detecting LF caused by various etiologies, such as NAFLD score (NFS)((8)) and BARD score((9)) for NAFLD.”
• Magnetic Resonance Imaging More Accurately Classifies Steatosis and Fibrosis in Patients With Nonalcoholic Fatty Liver Disease Than Transient Elastography. (2016, methodology): “Scoring Systems Based on a review of the literature, the following scores were calculated for each patient: FIB4 index [37]; NAFLD fibrosis score (NFS) [38]; aspartate aminotransferase (AST) to platelet ratio index (APRI) [39], AST-to- alanine transaminase (ALT) ratio (AAR), and the BARD score [40].”
• EASL-ALEH Clinical Practice Guidelines: Non-invasive tests for evaluation of liver disease severity and prognosis. (2015, background): “Several other scores or algorithms have been proposed in hepatitis C virus (HCV) [22–35], as well as in hepatitis B virus (HBV) [36,37], human immunodeficiency virus (HIV)-HCV coinfection [38,39], and NAFLD [40,41].”
• A position statement on NAFLD/NASH based on the EASL 2009 special conference. (2010, background): “Proprietary tests validated on larger cohorts (FibroTest [100], ELF panel [101], and FibroMeter fatty liver [102]) as well as more simple clinical scores are available [40,103,104].”
• EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. (2016, neutral): “Harrison, 2008 [42] BARD BMI, AST/ALT, DM 827 2-4 0.”